U.K. - DART-AD
Dementia AP Reduction Trial
•Enrolled residents of nursing or residential homes in four
•areas (2001-2004); followed patients to April 2006
•
•All patients had been diagnosed with possible or
•probable Alzheimer’s and all had taken APs for
•≥ 3 months (APs = risperidone, thioridazine, haloperidol,
•trifluoperazine, or chlorpromazine)
•
•Mean duration of drug use: 25 months
•
Union%2520jack Union%2520jack
In 2009, Ballard et al reported the results of the Dementia Antipsychotic Reduction Trial (DART-AD) – a novel study performed among dementia patients in four different regions of the U.K.

At the time of entry into the study, all of the patients had been diagnosed with possible or probable Alzheimer’s disease, and all of them had consumed an antipsychotic drug for at least three months.

Mean duration of drug use:     25 months